drug
febuxostat
Marketedupdated 5mo agoby Novadoz Pharmaceuticals LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying febuxostat
- phase3A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients
- phase2Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
- phase2The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
- phase2Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia
- phase3Tigulixostat (IBI128) vs Febuxostat in Gout
- phase2Boosting Osimertinib Blood Brain Barrier Penetration
- phase3Clinical Study of HR091506 Tablets in Treatment of Gout With Hyperuricemia in Adults
- phase1Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 8, 2031
~4.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Sep 8, 2031method-of-use (U-1346)US 83728724.9y
- Sep 8, 2031method-of-use (U-1346)US 83728724.9y
- Sep 8, 2031method-of-use (U-1346)US 91079124.9y
- Sep 8, 2031method-of-use (U-1346)US 91079124.9y
News(2)
- Crystalys nets $130M more to push gout drug through late-stage testsThe startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in t…biopharma_dive · 2mo ago
- Crystalys mines $130M series B to push gout drug through phase 3Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.fiercebiotech · 2mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that